Held in conjunction with the American Diabetes Association’s 85th Scientific Sessions
Saturday, June 21, 2025
6:15 PM – 6:30 PM CT Registration & Dinner
6:30 PM – 8:00 PM CT CE Symposium
Hyatt Regency McCormick Place Chicago
2233 S. Martin Luther King Drive
Chicago, IL 60616
Meeting Room: Regency Ballroom CDE
PROGRAM FEATURES
- Downloadable animations
- Interactive, case-based learning environment
- Create-your-own personalized poster
PRESENTING FACULTY
 |
Kimber Simmons, MD, MS Associate Professor of Pediatrics Barbara Davis Center for Diabetes Aurora, CO |
 |
Linda A. DiMeglio, MD Pediatric Endocrinology & Diabetology Riley Children’s Health Indiana University Health Indianapolis, IN |
PROGRAM OVERVIEW
This program will provide an expert overview of the importance of screening and detection of early-stage type 1 diabetes (T1D), as well as monitoring post-screening as a crucial step to identifying individuals who can benefit from treatment with disease-modifying therapies (DMTs). In addition, the program will overview the evidence with DMTs in early stage T1D, as well as patient selection and practical considerations for their application to patient care. The program will be highly interactive, including case-based discussions and engaging animations, which will help reinforce key concepts in early stage T1D.
TARGET AUDIENCE
This activity is designed to meet the educational needs of multidisciplinary clinicians who refer, treat or see patients with or at high risk for T1D is needed, including primary care clinicians, pediatricians, pediatric & adult endocrinologists, diabetes educators, infusion professionals and other allied healthcare professionals
LEARNING OBJECTIVES
After completing the activity, learners should be better able to:
- Incorporate evidence-based strategies for presymptomatic T1D screening into routine clinical practice to improve early detection.
- Interpret T1D screening results and effectively communicate next steps to support patient education and inform treatment decisions.
- Identify appropriate patients who would benefit from treatment with disease-modifying therapies for delaying T1D progression based on clinical evidence.
- Implement protocols to support safe and efficient administration of disease-modifying therapies for T1D according to guidance and patient-specific factors.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 1.5 ANCC contact hours.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 CPEU.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event Staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to the live event at [email protected]
